José María founded PharmaMar in 1986 and is currently the Chairman of the Board of Directors and Executive President.
He has been a Professor of Biochemistry at the Complutense University of Madrid and the University of Santiago de Compostela, he obtained an MBA from the IESE Business School in Madrid. Dr. Fernández Sousa-Faro has over 90 scientific articles and patents in the field of biochemistry, drug discovery and molecular biology. With more than 35 years of experience in the pharmaceutical industry, he has held positions within the executive management of ICI-Farma, Antibióticos, Zeltia and PharmaMar.
He was a member of the Board of Directors of Antibiotics, Penibérica, Biolys, ICI-Farma, Pescanova, Transfesa, Cooper–Zeltia, ICI-Zeltia and Banco Guipuzcoano.
She joined PharmaMar in 2005 and is Group Corporate Affairs Director since 2020. She sits on the Board of Sylentis and is an independent Board member of Biocross SL.
Previously, she was Director of Market Research and, between 2015-2018, General Manager and Board Member (2014-2018) of Xylazel. Between 2006 and 2014, she was General Manager of Noscira, a biotechnology company in the group dedicated to R&D.
Previously she was Manager and Technical Director of Qualysite Consultores., a company that she co-founded. Previously, she worked in a Contract Research Organisation, Cibest between 1997 and 2001).
She belongs to the Spanish Association of Pharmaceutical Medicine, of which she was president from 2013 to 2015, and for 20 years has been on the teaching committee of the Master Course in Clinical Trials Monitoring at the Madrid Professional Association of Pharmacists.
She holds a PhD in Pharmacy from the Universidad Complutense de Madrid.
Dr. Jimeno rejoined PharmaMar in 2020 in the virology unit. He is a medical oncologist, and holds a PhD from the University of Barcelona. From 2015, Dr. Jimeno served as Chief Medical Officer at Phosplatin Therapeutics, and remains part of its Scientific Advisory He was formerly VP of Clinical and Scientific Development at PharmaMar, responsible for developing Yondelis®, which is approved in over 80 countries including the US and EU, and the development of Aplidin® which is approved in Australia for multiple myeloma.
Previously he worked at Farmitalia Carlo Erba and US Biosciences. Most recently, Dr Jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company where he was involved in developing their EGFR diagnostic approved by the FDA. Dr. Jimeno has published over 100 papers in peer review journals on cancer and is a guest lecturer in immunology at The University of Zaragoza in Spain.